Preclinical studies in mouse models of hepatocellular and liver cancer demonstrate that CCR2 antagonists reduce TAM populations and increase infiltration of CD8+ T cells, further promoting anti-tumor immunity (187, 188). Here, CD8A is linked to neoplasm.